Follow the people · Insider
Lynn A. Tetrault
Lynn A. Tetrault files insider transactions with the SEC as a director of Alumis (ALMS). We hold 3 disclosed purchases and sales filed since 15 July 2015, 3 of them in the last 90 days.
- Files forALMS
- Disclosed buys and sells3 in all, 3 in the last 90 days
- Last disclosure2 July 2026
Positions held
4 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 30 July 2025 — 30 June 2026Director · Alumis (ALMS)3 Form 4 lines · source: SEC Form 4
- Filed 9 December 2020 — 24 June 2026Director · Rhythm Pharmaceuticals (RYTM)37 Form 4 lines · source: SEC Form 4
- Filed 15 July 2015 — 15 June 2026Director · Neogenomics (NEO)56 Form 4 lines · source: SEC Form 4
- Filed 18 December 2023 — 21 May 2025Director · Acelyrin (SLRN)4 Form 4 lines · source: SEC Form 4
Everything they disclosed
100 entries, newest first — one per disclosure report, one per Form 4 line- was granted 3,553 shares of AlumisSEC Form 42 July 2026Common Stock · traded 30 June 2026 · filed 2 July 2026
- was granted 15,528 shares of Alumis (a derivative holding)SEC Form 42 July 2026Stock Option (Right to Buy) · traded 30 June 2026 · filed 2 July 2026
- exercised options over 4,712 shares of Rhythm PharmaceuticalsSEC Form 425 June 2026Common Stock · traded 23 June 2026 · filed 25 June 2026
- exercised options over 4,712 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 425 June 2026Restricted Stock Units · traded 23 June 2026 · filed 25 June 2026
- was granted 3,691 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 425 June 2026Stock Option (right to buy) · traded 24 June 2026 · filed 25 June 2026
- was granted 2,324 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 425 June 2026Restricted Stock Units · traded 24 June 2026 · filed 25 June 2026
- exercised options over 37,000 shares of Rhythm PharmaceuticalsSEC Form 424 June 2026Common Stock · traded 22 June 2026 · filed 24 June 2026
- ▼ sold on the open market 37,000 shares of Rhythm PharmaceuticalsSEC Form 424 June 2026Common Stock · traded 22 June 2026 · filed 24 June 2026
- exercised options over 37,000 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 424 June 2026Stock Option (right to buy) · traded 22 June 2026 · filed 24 June 2026
- ▼ sold on the open market 5,307 shares of NeogenomicsSEC Form 417 June 2026Common Stock · traded 15 June 2026 · filed 17 June 2026
- ▼ sold on the open market 5,307 shares of NeogenomicsSEC Form 411 June 2026Common Stock · traded 9 June 2026 · filed 11 June 2026
- exercised options over 23,077 shares of NeogenomicsSEC Form 43 June 2026Common Stock · traded 1 June 2026 · filed 3 June 2026
- exercised options over 23,077 shares of Neogenomics (a derivative holding)SEC Form 43 June 2026Restricted Stock Unit · traded 1 June 2026 · filed 3 June 2026
- was granted 11,069 shares of Neogenomics (a derivative holding)SEC Form 43 June 2026Stock Option (Right to Buy) · traded 1 June 2026 · filed 3 June 2026
- was granted 15,970 shares of Neogenomics (a derivative holding)SEC Form 43 June 2026Restricted Stock Unit · traded 1 June 2026 · filed 3 June 2026
- was granted 49,800 shares of Alumis (a derivative holding)SEC Form 41 August 2025Stock Option (Right to Buy) · traded 30 July 2025 · filed 1 August 2025
- was granted 7,037 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 426 June 2025Stock Option (right to buy) · traded 24 June 2025 · filed 26 June 2025
- was granted 4,712 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 426 June 2025Restricted Stock Units · traded 24 June 2025 · filed 26 June 2025
- exercised options over 4,000 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 423 June 2025Restricted Stock Units · traded 18 June 2025 · filed 23 June 2025
- exercised options over 4,000 shares of Rhythm PharmaceuticalsSEC Form 423 June 2025Common Stock · traded 18 June 2025 · filed 23 June 2025
- exercised options over 12,254 shares of Neogenomics (a derivative holding)SEC Form 43 June 2025Restricted Stock Unit · traded 1 June 2025 · filed 3 June 2025
- was granted 16,107 shares of Neogenomics (a derivative holding)SEC Form 43 June 2025Stock Option (Right to Buy) · traded 1 June 2025 · filed 3 June 2025
- was granted 23,077 shares of Neogenomics (a derivative holding)SEC Form 43 June 2025Restricted Stock Unit · traded 1 June 2025 · filed 3 June 2025
- exercised options over 12,254 shares of NeogenomicsSEC Form 43 June 2025Common Stock · traded 1 June 2025 · filed 3 June 2025
- returned to the issuer 43,680 shares of Acelyrin (a derivative holding)SEC Form 423 May 2025Director Stock Option (right to buy) · traded 21 May 2025 · filed 23 May 2025
- returned to the issuer 89,955 shares of Acelyrin (a derivative holding)SEC Form 423 May 2025Director Stock Option (right to buy) · traded 21 May 2025 · filed 23 May 2025
- ▲ bought on the open market 7,000 shares of NeogenomicsSEC Form 49 May 2025Common Stock · traded 9 May 2025 · filed 9 May 2025
- exercised options over 3,199 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 411 September 2024Stock Option (right to buy) · traded 9 September 2024 · filed 11 September 2024
- exercised options over 10,000 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 411 September 2024Stock Option (right to buy) · traded 10 September 2024 · filed 11 September 2024
- exercised options over 7,501 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 411 September 2024Stock Option (right to buy) · traded 10 September 2024 · filed 11 September 2024
- exercised options over 3,199 shares of Rhythm PharmaceuticalsSEC Form 411 September 2024Common Stock · traded 9 September 2024 · filed 11 September 2024
- ▼ sold on the open market 3,199 shares of Rhythm PharmaceuticalsSEC Form 411 September 2024Common Stock · traded 9 September 2024 · filed 11 September 2024
- exercised options over 10,000 shares of Rhythm PharmaceuticalsSEC Form 411 September 2024Common Stock · traded 10 September 2024 · filed 11 September 2024
- exercised options over 7,501 shares of Rhythm PharmaceuticalsSEC Form 411 September 2024Common Stock · traded 10 September 2024 · filed 11 September 2024
- ▼ sold on the open market 8,490 shares of Rhythm PharmaceuticalsSEC Form 411 September 2024Common Stock · traded 10 September 2024 · filed 11 September 2024
- ▼ sold on the open market 8,661 shares of Rhythm PharmaceuticalsSEC Form 411 September 2024Common Stock · traded 10 September 2024 · filed 11 September 2024
- ▼ sold on the open market 350 shares of Rhythm PharmaceuticalsSEC Form 411 September 2024Common Stock · traded 10 September 2024 · filed 11 September 2024
- exercised options over 4,300 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 428 August 2024Stock Option (right to buy) · traded 26 August 2024 · filed 28 August 2024
- exercised options over 4,300 shares of Rhythm PharmaceuticalsSEC Form 428 August 2024Common Stock · traded 26 August 2024 · filed 28 August 2024
- ▼ sold on the open market 4,300 shares of Rhythm PharmaceuticalsSEC Form 428 August 2024Common Stock · traded 26 August 2024 · filed 28 August 2024
- exercised options over 10,000 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 414 August 2024Stock Option (right to buy) · traded 12 August 2024 · filed 14 August 2024
- exercised options over 10,000 shares of Rhythm PharmaceuticalsSEC Form 414 August 2024Common Stock · traded 12 August 2024 · filed 14 August 2024
- ▼ sold on the open market 9,593 shares of Rhythm PharmaceuticalsSEC Form 414 August 2024Common Stock · traded 12 August 2024 · filed 14 August 2024
- ▼ sold on the open market 407 shares of Rhythm PharmaceuticalsSEC Form 414 August 2024Common Stock · traded 12 August 2024 · filed 14 August 2024
- exercised options over 11,336 shares of Neogenomics (a derivative holding)SEC Form 413 August 2024Restricted Stock Unit · traded 10 August 2024 · filed 13 August 2024
- exercised options over 11,336 shares of NeogenomicsSEC Form 413 August 2024Common Stock · traded 10 August 2024 · filed 13 August 2024
- exercised options over 3,000 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 425 June 2024Restricted Stock Units · traded 21 June 2024 · filed 25 June 2024
- exercised options over 3,000 shares of Rhythm PharmaceuticalsSEC Form 425 June 2024Common Stock · traded 21 June 2024 · filed 25 June 2024
- was granted 14,000 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 420 June 2024Stock Option (right to buy) · traded 18 June 2024 · filed 20 June 2024
- was granted 4,000 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 420 June 2024Restricted Stock Units · traded 18 June 2024 · filed 20 June 2024
- was granted 43,680 shares of Acelyrin (a derivative holding)SEC Form 411 June 2024Director Stock Option (right to buy) · traded 7 June 2024 · filed 11 June 2024
- was granted 8,672 shares of Neogenomics (a derivative holding)SEC Form 44 June 2024Stock Option (Right to Buy) · traded 1 June 2024 · filed 4 June 2024
- was granted 12,254 shares of Neogenomics (a derivative holding)SEC Form 44 June 2024Restricted Stock Unit · traded 1 June 2024 · filed 4 June 2024
- ▼ sold on the open market 6,112 shares of NeogenomicsSEC Form 46 March 2024Common Stock · traded 4 March 2024 · filed 6 March 2024
- was granted 89,955 shares of Acelyrin (a derivative holding)SEC Form 420 December 2023Director Stock Option (right to buy) · traded 18 December 2023 · filed 20 December 2023
- was granted 8,353 shares of Neogenomics (a derivative holding)SEC Form 414 August 2023Stock Option (Right to Buy) · traded 10 August 2023 · filed 14 August 2023
- was granted 11,336 shares of Neogenomics (a derivative holding)SEC Form 414 August 2023Restricted Stock Unit · traded 10 August 2023 · filed 14 August 2023
- was granted 14,000 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 423 June 2023Stock Option (right to buy) · traded 21 June 2023 · filed 23 June 2023
- was granted 3,000 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 423 June 2023Restricted Stock Units · traded 21 June 2023 · filed 23 June 2023
- exercised options over 1,507 shares of Neogenomics (a derivative holding)SEC Form 424 May 2023Stock Option (Right to Buy) · traded 22 May 2023 · filed 24 May 2023
- exercised options over 1,507 shares of NeogenomicsSEC Form 424 May 2023Common Stock · traded 22 May 2023 · filed 24 May 2023
- was granted 13,882 shares of Neogenomics (a derivative holding)SEC Form 414 June 2022Stock Option (Right to Buy) · traded 10 June 2022 · filed 14 June 2022
- was granted 15,556 shares of NeogenomicsSEC Form 414 June 2022Common Stock · traded 10 June 2022 · filed 14 June 2022
- was granted 20,000 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 410 June 2022Stock Option (right to buy) · traded 8 June 2022 · filed 10 June 2022
- exercised options over 3,334 shares of Neogenomics (a derivative holding)SEC Form 420 May 2022Stock Option (Right to Buy) · traded 18 May 2022 · filed 20 May 2022
- exercised options over 3,334 shares of NeogenomicsSEC Form 420 May 2022Common Stock · traded 18 May 2022 · filed 20 May 2022
- was granted 972 shares of Neogenomics (a derivative holding)SEC Form 413 October 2021Stock Option (Right to Buy) · traded 11 October 2021 · filed 13 October 2021
- was granted 838 shares of NeogenomicsSEC Form 413 October 2021Common Stock · traded 11 October 2021 · filed 13 October 2021
- exercised options over 1,389 shares of NeogenomicsSEC Form 414 June 2021Common Stock · traded 11 June 2021 · filed 14 June 2021
- exercised options over 1,389 shares of Neogenomics (a derivative holding)SEC Form 414 June 2021Stock Option (Right to Buy) · traded 11 June 2021 · filed 14 June 2021
- was granted 15,000 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 411 June 2021Stock Option (right to buy) · traded 9 June 2021 · filed 11 June 2021
- was granted 3,081 shares of NeogenomicsSEC Form 44 June 2021Common Stock · traded 2 June 2021 · filed 4 June 2021
- was granted 3,714 shares of Neogenomics (a derivative holding)SEC Form 44 June 2021Stock Option (Right to Buy) · traded 2 June 2021 · filed 4 June 2021
- was granted 37,000 shares of Rhythm Pharmaceuticals (a derivative holding)SEC Form 411 December 2020Stock Option (Right to Buy) · traded 9 December 2020 · filed 11 December 2020
- was granted 3,448 shares of Neogenomics (a derivative holding)SEC Form 41 June 2020Stock Options (Right to Buy) · traded 28 May 2020 · filed 1 June 2020
- was granted 2,698 shares of NeogenomicsSEC Form 41 June 2020Common Stock · traded 28 May 2020 · filed 1 June 2020
- was granted 4,269 shares of Neogenomics (a derivative holding)SEC Form 410 June 2019Stock Options (Right to Buy) · traded 6 June 2019 · filed 10 June 2019
- was granted 3,419 shares of NeogenomicsSEC Form 410 June 2019Common Stock · traded 6 June 2019 · filed 10 June 2019
- ▼ sold on the open market 11,000 shares of NeogenomicsSEC Form 421 November 2018Common Stock · traded 19 November 2018 · filed 21 November 2018
- ▼ sold on the open market 2,000 shares of NeogenomicsSEC Form 421 November 2018Common Stock · traded 19 November 2018 · filed 21 November 2018
- exercised options over 10,000 shares of Neogenomics (a derivative holding)SEC Form 416 November 2018Stock Option (Right to Buy) · traded 15 November 2018 · filed 16 November 2018
- exercised options over 5,555 shares of Neogenomics (a derivative holding)SEC Form 416 November 2018Stock Option (Right to Buy) · traded 15 November 2018 · filed 16 November 2018
- exercised options over 3,333 shares of Neogenomics (a derivative holding)SEC Form 416 November 2018Stock Option (Right to Buy) · traded 15 November 2018 · filed 16 November 2018
- exercised options over 10,000 shares of NeogenomicsSEC Form 416 November 2018Common Stock · traded 15 November 2018 · filed 16 November 2018
- exercised options over 5,555 shares of NeogenomicsSEC Form 416 November 2018Common Stock · traded 15 November 2018 · filed 16 November 2018
- exercised options over 3,333 shares of NeogenomicsSEC Form 416 November 2018Common Stock · traded 15 November 2018 · filed 16 November 2018
- ▼ sold on the open market 5,000 shares of NeogenomicsSEC Form 416 November 2018Common Stock · traded 14 November 2018 · filed 16 November 2018
- was granted 15,564 shares of NeogenomicsSEC Form 45 June 2018Common Stock · traded 1 June 2018 · filed 5 June 2018
- was granted 3,017 shares of Neogenomics (a derivative holding)SEC Form 45 June 2018Common Stock · traded 1 June 2018 · filed 5 June 2018
- exercised options over 7,222 shares of NeogenomicsSEC Form 430 May 2017Common Stock · traded 30 May 2017 · filed 30 May 2017
- converted 2,150 shares of Neogenomics (a derivative holding)SEC Form 430 May 2017Restricted Stock · traded 30 May 2017 · filed 30 May 2017
- converted 5,072 shares of Neogenomics (a derivative holding)SEC Form 430 May 2017Restricted Stock · traded 30 May 2017 · filed 30 May 2017
- was granted 10,000 shares of Neogenomics (a derivative holding)SEC Form 430 May 2017Stock Option (Right to Buy) · traded 25 May 2017 · filed 30 May 2017
- was granted 8,667 shares of Neogenomics (a derivative holding)SEC Form 430 May 2017Restricted Stock · traded 25 May 2017 · filed 30 May 2017
- was granted 5,072 shares of Neogenomics (a derivative holding)SEC Form 429 July 2016Restricted Stock · traded 28 July 2016 · filed 29 July 2016
- was granted 8,333 shares of Neogenomics (a derivative holding)SEC Form 429 July 2016Stock Option (Right to Buy) · traded 28 July 2016 · filed 29 July 2016
- was granted 2,150 shares of NeogenomicsSEC Form 43 May 2016Common Stock · traded 20 April 2016 · filed 3 May 2016
- ▲ bought on the open market 9,500 shares of NeogenomicsSEC Form 423 December 2015Common Stock · traded 21 December 2015 · filed 23 December 2015
- ▲ bought on the open market 3,500 shares of NeogenomicsSEC Form 49 December 2015Common Stock · traded 7 December 2015 · filed 9 December 2015
- was granted 10,000 shares of Neogenomics (a derivative holding)SEC Form 415 July 2015Stock Option (Right to Buy) · traded 15 July 2015 · filed 15 July 2015
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.